# A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative Colitis

> **NCT06260267** · PHASE1 · WITHDRAWN · sponsor: **Ferring Pharmaceuticals**

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Microbiota suspension
- **DRUG:** Microbiota capsule
- **DRUG:** Placebo suspension
- **DRUG:** Placebo capsule

## Key facts

- **NCT ID:** NCT06260267
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-03-12
- **Primary completion:** 2026-01-15
- **Final completion:** 2026-01-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Not due to safety concerns, but changes in strategy which this trial no longer fulfills.
- **Last updated:** 2024-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06260267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06260267, "A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative Colitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06260267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*